{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:29Z","timestamp":1791388109780,"version":"4.3.3"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hydroxyurea (HU) is a commonly used first\u2010line treatment in patients with polycythemia vera (PV). However, approximately 15%\u201324% of PV patients report intolerance and resistance to HU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This phase IV, European, real\u2010world, observational study assessed the efficacy and safety of ruxolitinib in PV patients who were resistant and\/or intolerant to HU, with a 24\u2010month follow\u2010up. The primary objective was to describe the profile and disease burden of PV patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 350 enrolled patients, 70% were &gt;60\u2009years old. Most patients (59.4%) had received \u22651 phlebotomy in the 12\u2009months prior to the first dose of ruxolitinib. Overall, 68.2% of patients achieved hematocrit control with 92.3% patients having hematocrit &lt;45% and 35.4% achieved hematologic remission at month 24. 85.1% of patients had no phlebotomies during the study. Treatment\u2010related adverse events were reported in 54.3% of patients and the most common event was anemia (22.6%). Of the 10 reported deaths, two were suspected to be study drug\u2010related.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates that ruxolitinib treatment in PV maintains durable hematocrit control with a decrease in the number of phlebotomies in the majority of patients and was generally well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14124","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:54:11Z","timestamp":1698652451000},"page":"379-391","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ruxolitinib in patients with polycythemia vera resistant and\/or intolerant to hydroxyurea: European observational study"],"prefix":"10.1111","volume":"112","author":[{"given":"Alexandre","family":"Theocharides","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital Zurich and University of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-7629","authenticated-orcid":false,"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Hematology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Radiological and Hematological Sciences Catholic University, Fondazione Policlinico A Gemelli IRCCS  Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Accurso","sequence":"additional","affiliation":[{"name":"U.O.C. Ematologia AZ.Osp.Univ. Policlinico Paolo Giaccone Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[{"name":"Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-417X","authenticated-orcid":false,"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5880","authenticated-orcid":false,"given":"Miklos","family":"Egyed","sequence":"additional","affiliation":[{"name":"Hematol\u00f3giai Oszt\u00e1ly Somogy Megyei Kaposi Mor Oktato Korhaz  Kaposvar Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie CHU de Brest  Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina Garcia","family":"Delgado","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia Hospital Virgen de la Victoria  Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Cantoni","sequence":"additional","affiliation":[{"name":"Division of Oncology, Hematology and Transfusion Medicine Kantonsspital Aarau  Aarau Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders E. A.","family":"Dahm","sequence":"additional","affiliation":[{"name":"Avdeling for Blodsykdommer Akershus Universitetssykehus  L\u00f8renskog Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damianos","family":"Sotiropoulos","sequence":"additional","affiliation":[{"name":"Heamatology Clinic General Hospital of Thessaloniki G Papanikolaou  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Houtsma","sequence":"additional","affiliation":[{"name":"Novartis Global Service Center  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Smyth","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals AG  Basel Switzerland"},{"name":"Novartis Pharmaceuticals UK Limited  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Novartis Global Service Center  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Di Matteo","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA  Origgio Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Zuurman","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. W.","family":"te Boekhorst","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406186"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.062"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2357-4"},{"issue":"2","key":"e_1_2_10_6_1","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol"},{"issue":"9","key":"e_1_2_10_7_1","first-page":"2139","article-title":"Polycythemia vera","volume":"69","author":"Stuart BJ","year":"2004","journal-title":"Am Fam Physician"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1045869"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208500"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.05.003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-429134"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9337"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"issue":"2","key":"e_1_2_10_18_1","first-page":"261","article-title":"Safety profile of hydroxyurea in the treatment of patients with Philadelphia\u2010negative chronic myeloproliferative disorders","volume":"90","author":"Randi ML","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387787"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13886"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00046-1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12256"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143644"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01935"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750346"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:26:45Z","timestamp":1708050405000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/ejh.14124"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14124","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"2023-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}